Brit J Cancer: Male breast cancer patients benefit from survival with tamoxifen treatment

Due to the lack of forward-looking data, current treatment for male breast cancer (MBC) is based primarily on retrospective analysis or information from female patient studiesIn a recent study published in the journal British Journal of Cancer, an authoritative journal of the field of oncology, researchers looked retrospectively at the survival of tamoxifen in MBC patientsin this prospective cohort study, from May 2009 to June 2018, researchers treated 448 patients with MBC, the main endpoint of which was disease-free survival (DFS)between May 2009 and June 2018, researchers identified 448 breast cancer patients with a median age of 69 (27-96 years) at the time of diagnosisThe median follow-up time is 39 months (range 3-89 months)Most tumors are larger than 20mmThere are no special histology types for invasive catheter cancer, which is moderately dividedAlmost half of male patients were diagnosed with positive lymph nodes in the armpits (43.5%)Hormone receptors (HR) were observed positive in 98.4% of patientsIt is worth noting that compared to men who received tamoxifen treatment, men who did not receive tamoxifen were significantly lower in DFS (P-0.002)The recurrence and mortality rates of patients treated with tamoxifen were 18.2% and 11.2%, respectivelyThe most common area of metastasis is the boneAfter adjusting for the prognosis, the researchers found that tamoxifen reduced the recurrence rate by 68% (risk ratio HR s 0.32; 95% confidence interval was 0.14-0.74)thus shows that tamoxifen treatment is associated with dFS improvement in MBC patients